The Accelerated Access Review recommendations are currently being considered by the Government. As the hon. Member will be aware from the Westminster Hall Debate on 13 December, it was stated that the National Institute for Health and Care Excellence (NICE) would be happy to consider any additional evidence of the cost-effectiveness or a revised price proposal that Vertex can provide to support a review of NICE’s original decision on the use of Orkambi (lumacaftor-ivacaftor). In the meantime discussions with Vertex are continuing, including with NHS England.